KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Switzerland, discusses KEYNOTE-010, a phase 2/3 clinical trial that was designed to compare pembrolizumab, an anti-PD-1 antibody, against docetaxel, a commonly used chemotherapy, for patients with PD-L1-positive non-small cell lung cancer (NSCLC) after platinum-based therapy.